REGENXBIO (RGNX) Q4 2025 Earnings Call Transcript
2026-03-05 11:23:35 ET
Image source: The Motley Fool.
Thursday, March 5, 2026 at 8 a.m. ET
REGENXBIO (NASDAQ:RGNX) provided operational updates highlighting late-stage clinical, regulatory, and financial developments that may influence investor sentiment and near-term strategy. The RGX-202 Duchenne pivotal trial reached full enrollment, with management emphasizing data indicating both functional and biomarker improvements, and advanced FDA interactions ahead of an anticipated accelerated approval pathway. Company leadership outlined Cirovec’s topline data readout schedules, a potential $100 million milestone upon first dosing in diabetic retinopathy, and noted durable efficacy and significant anti-VEGF injection reduction in prior dose cohorts. Management acknowledged ongoing regulatory challenges in the MPS franchise, reporting active engagement with the FDA following a clinical hold and a single observed AAV integration event temporally associated with tumor formation. Financially, the company cited partnership-based revenues, committed R&D investments, and a multi-year cash runway, noting further extension potential with upcoming milestones.
NASDAQ: RGNX
RGNX Trading
24.73% G/L:
$10.49 Last:
1,126,177 Volume:
$9.75 Open:
